Unfortunately, clinical evaluation and diagnostic tests sometimes fail to determine whether a necrotizing myopathy is immune mediated, resulting in undertreatment of autoimmune myopathies or ...

Can We Differentiate Those Who Have the Self-limited Form of Statin Myopathy From Those Who Have the Immune-Mediated Variety? In our experience, most patients with autoimmune statin myopathy had ...

CCAR-168 is under clinical development by AbelZeta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...

YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.